Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors

Sci Adv. 2024 Mar;10(9):eadn0042. doi: 10.1126/sciadv.adn0042. Epub 2024 Mar 1.

Abstract

People living with human immunodeficiency virus (HIV) receiving integrase strand transfer inhibitors (INSTIs) have been reported to experience virological failure in the absence of resistance mutations in integrase. To elucidate INSTI resistance mechanisms, we propagated HIV-1 in the presence of escalating concentrations of the INSTI dolutegravir. HIV-1 became resistant to dolutegravir by sequentially acquiring mutations in the envelope glycoprotein (Env) and the nucleocapsid protein. The selected Env mutations enhance the ability of the virus to spread via cell-cell transfer, thereby increasing the multiplicity of infection (MOI). While the selected Env mutations confer broad resistance to multiple classes of antiretrovirals, the fold resistance is ~2 logs higher for INSTIs than for other classes of drugs. We demonstrate that INSTIs are more readily overwhelmed by high MOI than other classes of antiretrovirals. Our findings advance the understanding of how HIV-1 can evolve resistance to antiretrovirals, including the potent INSTIs, in the absence of drug-target gene mutations.

MeSH terms

  • HIV Integrase Inhibitors* / pharmacology
  • HIV Integrase* / genetics
  • HIV Integrase* / metabolism
  • HIV-1* / genetics
  • HIV-1* / metabolism
  • Humans
  • Mutation
  • Raltegravir Potassium / pharmacology

Substances

  • Raltegravir Potassium
  • HIV Integrase Inhibitors
  • HIV Integrase